Ampio (AMPE) Gets Additional Patent for Ampion
Tweet
Share
E-mailGet Alerts AMPE Hot Sheet
Join SI Premium – FREE
Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), has received notice of allowance from the US Patent Office of an additional patent that complements and expands its anti inflammatory patent portfolio for its lead drug Ampion.
Gary Connell, Ampio patent counsel from Sheridan Ross PC of Denver stated: "The allowed claims in this new patent protect pharmaceutical compositions that include the use of the low molecular weight fraction of commercially available (approved) human serum albumin for any use, including the injectable used in the osteoarthritis of the knee study conducted in Australia. The allowed patent claims further strengthen Ampio's patent portfolio by providing specific coverage for a pharmaceutical composition produced using the same method by which the Ampion™ product in clinical trials was produced."
Gary Connell, Ampio patent counsel from Sheridan Ross PC of Denver stated: "The allowed claims in this new patent protect pharmaceutical compositions that include the use of the low molecular weight fraction of commercially available (approved) human serum albumin for any use, including the injectable used in the osteoarthritis of the knee study conducted in Australia. The allowed patent claims further strengthen Ampio's patent portfolio by providing specific coverage for a pharmaceutical composition produced using the same method by which the Ampion™ product in clinical trials was produced."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sky Quarry names Heidi Bowman as CFO
- Westlake Corp adds dual listing on NYSE Texas exchange
- UDynamics files for Nasdaq IPO of 5.6 million shares at $5-$7 per share
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
